Borregaard (BRG) SEB Nordic Seminar presentation summary
Event summary combining transcript, slides, and related documents.
SEB Nordic Seminar presentation summary
16 Jan, 2026Company background and market position
Founded in 1889 in Norway, with over 135 years of experience and a history as one of Norway's largest companies for over 60 years.
Operates the world's most advanced biorefinery, fully utilizing sustainable Norway Spruce as raw material.
Employs 1,150 people, with business in 13 countries and sales to 100 countries, generating 7.6 billion NOK turnover and 1.9 billion NOK EBITDA.
Business model, strategy, and innovation
Biorefinery model focuses on high value-added products through full raw material utilization and diversified markets.
Specializes as a global niche player in markets with high entry barriers, leveraging application knowledge and proximity to markets.
Strong innovation and continuous improvement are core, with competence as a key competitive advantage.
Strategic priorities include increased specialisation, value growth, and targeted investments in capacity and new initiatives.
Product portfolio and market reach
Leading supplier of lignin-based biopolymers, only producer of wood-based vanillin, and pioneer in cellulose fibrils.
Product applications span agriculture, construction, food & pharma, chemicals, and fine chemicals.
Sales distribution in 2024: Europe 46%, Americas 30%, Asia 23%, Rest of World 1%.
Latest events from Borregaard
- Record EBITDA, strong cash flow, higher dividend, and start-up impairments define the period.BRG
Q4 20254 Feb 2026 - BioSolutions strength offset weaker BioMaterials; outlook cautious amid rising costs.BRG
Q2 20243 Feb 2026 - Specialization, innovation, and sustainability drive robust growth and disciplined investment.BRG
CMD 202420 Jan 2026 - Q3 revenue and EBITDA rose on volume growth and expansion, but cost and market risks remain.BRG
Q3 202417 Jan 2026 - Record EBITDA and higher dividend driven by BioSolutions, with strong outlook for 2025.BRG
Q4 20249 Jan 2026 - 2025 outlook: stable volumes, higher biomaterials prices, lower bioethanol prices, and cost risks.BRG
Pre-Close Call26 Dec 2025 - Q4 guidance remains steady, with strong margins and lower costs offset by ongoing legal and market risks.BRG
Pre-Close Call18 Dec 2025 - Record BioSolutions results and improved margins drove EBITDA to NOK 511 million.BRG
Q1 202529 Nov 2025 - Growth in agriculture and specialization offset tariff risks, with strong currency hedging benefits.BRG
Pre-Close Call12 Nov 2025